A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
Clinical trial NCT04108195 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04108195
- Sponsor
- Janssen Research & Development, LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-02-21
- Primary completion
- 2027-04-07
- Enrollment
- 290
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.